This study also provides a clear basis for the use of a novel anti-platelet agent, exogenous CO, as an effective strategy for improving platelet function and support, a model (Fig. 7) in which the glycoprotein-mediated PI3K-Akt-GSK-3β pathway effectively regulates platelet activation during sepsis. The gene discussed is GSK3B; the disease is Sepsis.